SCHEMBL12096777

SCHEMBL12096777

CN1CCOc2ccc(S(=O)(=O)n3c(C(O)c4ccc(C(=O)O)cc4)cc4cc(C(F)(F)F)ccc43)cc21

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 7/20 0.48
▸ PPARA Q07869 7/20 0.48
▸ PPARD Q03181 6/20 0.48
▸ USP9X Q93008 2/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PAX8 Q06710 1/20 0.41
▸ PKM P14618 3/20 0.40
▸ PKLR P30613 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CPT2 P23786 2/20 0.36
▸ CPT1A P50416 2/20 0.36
▸ KLKB1 P03952 1/20 0.35
▸ CPT1B Q92523 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096870 0.84 PPARG (0.55) PPARGPPARAPPARDUSP9XKMT2A
SCHEMBL12096867 0.81 PPARG (0.47) PPARGPPARAPPARD
SCHEMBL12096761 0.80 PPARG (0.54) PPARGPPARAPPARDKMT2APAX8
SCHEMBL12096733 0.79 PPARG (0.58) PPARGPPARAPPARDKMT2APAX8
SCHEMBL12096771 0.78 PPARG (0.45) PPARGPPARAPPARDCPT2CPT1A
SCHEMBL12096891 0.78 PPARG (0.45) PPARGPPARAPPARDCPT2CPT1A
SCHEMBL12096734 0.77 PPARG (0.56) PPARGPPARAPPARDKMT2APAX8
SCHEMBL12096763 0.77 PPARG (0.54) PPARGPPARAPPARDKMT2APAX8
SCHEMBL12096890 0.77 PPARG (0.54) PPARGPPARAPPARDKMT2APAX8
SCHEMBL12096664 0.75 PPARG (0.52) PPARGPPARAPPARDKMT2APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A PPARG 423/4885PPARA 564/4885PPARD 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback